Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: not improved to a clinically important extent compared with other drugs (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: deterioration of symptoms compared with other drugs (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Beta‐blockers showed no clear difference in global state: 1. Leaving the study early ‐ Short term compared with placebo (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
Beta‐blockers showed no clear difference in global state: 2. Relapse ‐ short term compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 1. Death ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Death ‐ medium term · patients with schizophrenia
1 finding from 1 review
Adverse effect: 2. General ‐ Short term · patients with schizophrenia
Beta‐blockers showed no clear difference in adverse effect: 2. General ‐ Short term compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 3. Specific ‐ cardiovascular ‐ short term · patients with schizophrenia
Beta‐blockers showed no clear difference in adverse effects: 3. Specific ‐ cardiovascular ‐ short term compared with placebo (low certainty).
1 finding from 1 review